Metronomic chemotherapy was originally defined as the chronic administration of chemotherapeutic drugs at relatively low, minimally toxic doses and with no prolonged drug-free breaks. It is by essence opposed to conventional chemotherapy, which is based on the administration of chemotherapy drugs slightly below or at the maximum-tolerated dose every 2 or 3 weeks.
Given the high sensitivity of vascular endothelial cells to chemotherapeutic drugs, it was hypothesized that more frequent administration of these drugs at lower doses would result in a potent inhibition of tumor angiogenesis and would prevent the rapid vascular rebound that often occurs during prolonged drug-free breaks following conventional chemotherapy. This gave rise to the concept of anti-angiogenic chemotherapy, which was then...
KeywordsChemotherapy Angiogenesis Resistance Immunity
- (2012) Maintenance chemotherapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin, p 2137. doi:10.1007/978-3-642-16483-5_6974Google Scholar
- (2012) Maximum tolerated dose. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin, p 2188. doi:10.1007/978-3-642-16483-5_3567Google Scholar
- (2012) Palliative care. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2759. doi:10.1007/978-3-642-16483-5_4351Google Scholar
- (2012) Tumor-associated angiogenesis. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin, p 3807. doi:10.1007/978-3-642-16483-5_6016Google Scholar